Your browser doesn't support javascript.
Association between IL-6 and severe disease and mortality in COVID-19 disease: a systematic review and meta-analysis.
Liu, Xiaohui; Wang, Hongwei; Shi, Si; Xiao, Jinling.
  • Liu X; The Respiratory Department, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Wang H; The Respiratory Department, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Shi S; The Respiratory Department, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • Xiao J; The Respiratory Department, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Postgrad Med J ; 98(1165): 871-879, 2022 Nov 01.
Статья в английский | MEDLINE | ID: covidwho-1276990
ABSTRACT

BACKGROUND:

So far, SARS-CoV-2 is the seventh coronavirus found to infect humans and cause disease with quite a strong infectivity. Patients diagnosed as severe or critical cases are prone to multiple organ dysfunction syndrome, acute respiratory distress syndrome and even death. Proinflammatory cytokine IL-6 has been reported to be associated with the severity of disease and mortality in patients with COVID-19.

OBJECTIVE:

This systematic review and meta-analysis were carried out to evaluate the association between IL-6 and severe disease and mortality in COVID-19 disease.

METHODS:

A systematic literature search using China National Knowledge Infrastructure, Wanfang databases, China Science and Technology Journal Database, Chinese Biomedical Literature, Embase, PubMed and Cochrane Central Register of Controlled Trials was performed from inception until 16 January 2021.

RESULTS:

12 studies reported the value of IL-6 for predicting the severe disease in patients with COVID-19. The pooled area under the curve (AUC) was 0.85 (95% CI 0.821 to 0.931). 5 studies elaborated the predictive value of IL-6 on mortality. The pooled sensitivity, specificity and AUC were 0.15 (95% CI 0.13 to 0.17, I2=98.9%), 0.73 (95% CI 0.65 to 0.79, I2=91.8%) and 0.531 (95% CI 0.451 to 0.612), respectively. Meta-regression analysis showed that country, technique used, cut-off, sample, study design and detection time did not contribute to the heterogeneity of mortality.

CONCLUSION:

IL-6 is an adequate predictor of severe disease in patients infected with the COVID-19. The finding of current study may guide clinicians and healthcare providers in identifying potentially severe or critical patients with COVID-19 at the initial stage of the disease. Moreover, we found that only monitoring IL-6 levels does not seem to predict mortality and was not associated with COVID-19's mortality. PROSPERO REGISTRATION NUMBER CRD42021233649.
Тема - темы
ключевые слова

Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: COVID-19 Тип исследования: Диагностическое исследование / Экспериментальные исследования / Прогностическое исследование / Рандомизированные контролируемые испытания / Отзывы / Систематический обзор/метаанализ Пределы темы: Люди Страна как тема: Азия Язык: английский Журнал: Postgrad Med J Год: 2022 Тип: Статья Аффилированная страна: Postgradmedj-2021-139939

Документы, близкие по теме

MEDLINE

...
LILACS

LIS


Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: COVID-19 Тип исследования: Диагностическое исследование / Экспериментальные исследования / Прогностическое исследование / Рандомизированные контролируемые испытания / Отзывы / Систематический обзор/метаанализ Пределы темы: Люди Страна как тема: Азия Язык: английский Журнал: Postgrad Med J Год: 2022 Тип: Статья Аффилированная страна: Postgradmedj-2021-139939